---
layout: post
title: "Determination That Romidepsin Injection, 10 Milligrams/2 Milliliters (5 Milligrams/Milliliter) and 27.5 Milligrams/5.5 Milliliters (5 Milligrams/Milliliter), Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness"
date: 2026-02-05 19:08:38 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2024-05298
original_published: 2024-03-13 00:00:00 +0000
significance: 8.00
---

# Determination That Romidepsin Injection, 10 Milligrams/2 Milliliters (5 Milligrams/Milliliter) and 27.5 Milligrams/5.5 Milliliters (5 Milligrams/Milliliter), Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** March 13, 2024 00:00 UTC
**Document Number:** 2024-05298

## Summary

The Food and Drug Administration (FDA or Agency) has determined that Romidepsin Injection, 10 milligrams (mg)/2 milliliters (mL) (5 mg/mL) and 27.5 mg/5.5 mL (5 mg/mL), were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for romidepsin solution, 10 mg/2 mL (5 mg/mL) and 27.5 mg/5.5 mL (5 mg/mL), that refer to these drugs as long as they meet relevant legal and regulatory requirements.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2024/03/13/2024-05298/determination-that-romidepsin-injection-10-milligrams2-milliliters-5-milligramsmilliliter-and-275)
- API: https://www.federalregister.gov/api/v1/documents/2024-05298

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
